Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earnings
Skye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.
Check out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.
Both of these companies’ innovative products present excellent long-term opportunities for investors seeking growth in the stock market.
Financing expected to fund strategic expansion of obesity clinical development and extend operating runway beyond 2026San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB:...
San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercialization...